England’s National Institute for Health and Care Excellence (NICE) has recommended that the oral treatment Voydeya (danicopan) be covered…
Articles by Steve Bryson PhD
Long-term treatment with KP104, a first-in-class dual-function complement inhibitor, controlled red blood cell destruction occurring both inside and…
Onco360 will supply Voydeya (danicopan), an oral add-on medication for treating extravascular hemolysis (EVH), or red blood cell destruction…
The under-the-skin (subcutaneous) injection therapy crovalimab has been approved in China for adults and adolescents, ages 12 and older, with…
Fabhalta (iptacopan) and danicopan are two first-in-class treatments for paroxysmal nocturnal hemoglobinuria (PNH) that…
Long-term treatment with Soliris (eculizumab) safely and effectively reduced the severity of paroxysmal nocturnal hemoglobinuria (PNH) in Korean…
Paroxysmal nocturnal hemoglobinuria (PNH) developed in a young man after an asymptomatic infection with SARS-CoV-2, the virus that causes…
Treatment with OMS906 is showing an ability to normalize all markers of red blood cell destruction, or hemolysis, in severely…
Monthly injections of the experimental therapy crovalimab controlled red blood cell loss and the need for blood transfusions for up…
A single dose of Homology Medicines’ gene therapy candidate HMI-104 led to the sustained production of a therapeutic antibody…